These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 37556076)
1. Identification of the novel markers of PPAR signalling affecting immune microenvironment and immunotherapy response of lung adenocarcinoma patients. Zhang W; Liu J; Ren X; Zhang Z; Zhou M; Li Y; Wang J; Li Q; Zhu Q; Wu G J Cell Mol Med; 2024 Mar; 28(5):e17877. PubMed ID: 37556076 [TBL] [Abstract][Full Text] [Related]
2. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739 [TBL] [Abstract][Full Text] [Related]
3. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma. Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q Front Immunol; 2021; 12():693062. PubMed ID: 34497605 [TBL] [Abstract][Full Text] [Related]
4. Myeloid cell differentiation-related gene signature for predicting clinical outcome, immune microenvironment, and treatment response in lung adenocarcinoma. Wu D; Liu Y; Liu J; Ma L; Tong X Sci Rep; 2024 Jul; 14(1):17460. PubMed ID: 39075165 [TBL] [Abstract][Full Text] [Related]
5. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD. Ma C; Gu Z; Yang Y J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237 [TBL] [Abstract][Full Text] [Related]
6. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma. Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204 [TBL] [Abstract][Full Text] [Related]
7. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ Front Immunol; 2021; 12():724741. PubMed ID: 34335635 [TBL] [Abstract][Full Text] [Related]
8. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619 [TBL] [Abstract][Full Text] [Related]
9. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment. Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861 [TBL] [Abstract][Full Text] [Related]
10. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma. Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217 [TBL] [Abstract][Full Text] [Related]
11. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis. Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. Yu L; Cao S; Li J; Han B; Zhong H; Zhong R Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738 [TBL] [Abstract][Full Text] [Related]
13. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma. Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma. Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401 [TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma. Zuo S; Wei M; Wang S; Dong J; Wei J Front Immunol; 2020; 11():1218. PubMed ID: 32714316 [No Abstract] [Full Text] [Related]
16. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study. Chen G; Dong Z; Wu D; Chen Y J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059 [TBL] [Abstract][Full Text] [Related]
17. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma. Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484 [TBL] [Abstract][Full Text] [Related]
18. Identification and analysis of prognostic immune cell homeostasis characteristics in lung adenocarcinoma. Sun Y; Ma Q; Chen Y; Liao D; Kong F Clin Respir J; 2024 May; 18(5):e13755. PubMed ID: 38757752 [TBL] [Abstract][Full Text] [Related]
19. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer. Tian WJ; Liu SS; Li BR Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552 [TBL] [Abstract][Full Text] [Related]
20. G0 arrest gene patterns to predict the prognosis and drug sensitivity of patients with lung adenocarcinoma. Ma Y; Li Z; Li D; Zheng B; Xue Y PLoS One; 2024; 19(8):e0309076. PubMed ID: 39159158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]